modelJ07AG01
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | HaemophilusInfluenzaeBPurifiedAntigenConjugated | |
| ATC code: | J07AG01 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/hr |
| other parameters in model implementation | ||
Haemophilus influenzae type b (Hib) conjugate vaccine is a purified bacterial capsular polysaccharide (polyribosylribitol phosphate, PRP) conjugated to a protein carrier to enhance immunogenicity. It is used for immunization to protect against invasive diseases caused by Haemophilus influenzae type b, such as meningitis, pneumonia, and epiglottitis, particularly in infants and young children. The Hib vaccine is widely approved and routinely used in immunization schedules globally.
Pharmacokinetics
No published pharmacokinetic (PK) model exists for the Hib conjugate vaccine, as PK parameters such as absorption, distribution, metabolism, and excretion are generally not directly applicable to vaccines. Most available data are on immunogenicity, clinical efficacy, and antibody titer kinetics in infants and children, the primary population for vaccination.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)